In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will get treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. There might be increased treatment load for members During this trial https://abbv-744-brd4-inhibitor-m91346.izrablog.com/32504504/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know